诚达药业(301201) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 108,619,193.47, representing a 23.54% increase compared to CNY 87,920,036.48 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was CNY 26,229,854.86, up 25.28% from CNY 20,937,541.64 year-on-year[3]. - The company reported a basic earnings per share of CNY 0.2959, reflecting a 2.49% increase from CNY 0.2887 in the same period last year[3]. - Total operating revenue for the current period reached ¥108,619,193.47, an increase of 23.5% compared to ¥87,920,036.48 in the previous period[24]. - Net profit for the current period was ¥26,213,014.63, representing a 25.5% increase from ¥20,898,666.42 in the same period last year[25]. - The company reported a total comprehensive income of ¥26,213,014.63, an increase from ¥20,898,666.42 in the same period last year[26]. Cash Flow - The net cash flow from operating activities decreased by 32.09% to CNY 8,749,113.60, down from CNY 12,883,251.85 in the previous year[3]. - Cash received from sales increased by 34.19% to ¥101,851,387.79, driven by the growth in sales scale[10]. - Cash received from other operating activities surged by 776.52% to ¥9,918,069.62, primarily due to a significant increase in export tax rebates[10]. - Cash paid for purchasing goods and services rose by 95.91% to ¥66,040,231.08, attributed to increased raw material procurement[10]. - Cash paid to employees increased by 48.73% to ¥17,256,124.91, reflecting higher labor costs due to increased production[10]. - Cash paid for various taxes decreased by 65.25% to ¥3,601,585.01, as the previous period's disposal gains led to higher tax liabilities[10]. - Cash inflow from investment recoveries reached ¥50,000,000.00, marking a 100% increase due to the recovery of financial investments[10]. - Cash outflow for fixed asset purchases and construction rose by 106.36% to ¥44,564,424.20, linked to ongoing fundraising project developments[10]. - Cash inflow from the issuance of shares amounted to ¥1,640,224,998.21, resulting from the company's initial public offering[10]. - Cash outflow for debt repayment was ¥70,000,000.00, reflecting the repayment of loans during the period[10]. - Investment activities generated a net cash flow of -¥843,462,046.94, significantly lower than -¥21,487,285.80 in the prior period[29]. - Financing activities produced a net cash flow of ¥1,557,492,238.64, compared to -¥7,571,607.58 in the previous period[29]. Assets and Liabilities - Total assets at the end of Q1 2022 reached CNY 2,260,708,946.13, a significant increase of 230.89% from CNY 683,227,154.78 at the end of the previous year[3]. - The company's cash and cash equivalents reached ¥741,652,374.11, compared to ¥18,492,915.53 at the start of the year[20]. - Total current assets increased to ¥1,769,711,682.43 from ¥225,933,322.24, indicating strong liquidity growth[21]. - The company's total liabilities decreased from ¥153,299,903.71 to ¥82,934,901.82, reflecting improved financial health[22]. - Shareholders' equity attributable to the company increased by 311.36% to CNY 2,177,107,274.92 from CNY 529,243,641.45 at the end of the last year[3]. - Shareholders' equity rose significantly to ¥2,177,774,044.31 from ¥529,927,251.07, showcasing robust growth in owner’s equity[23]. - The company reported inventory of ¥123,407,364.02, up from ¥104,183,626.72, indicating increased stock levels[21]. - The company’s long-term investments in construction increased to ¥91,939,324.45 from ¥70,696,859.84, indicating ongoing expansion efforts[21]. Expenses - The company’s marketing expenses surged by 119.58% to CNY 1,657,986.57, attributed to increased marketing efforts and insurance costs[9]. - The company’s financial expenses improved, showing a decrease of 239.92% to -CNY 281,864.76 due to reduced loan interest and increased deposit interest[9]. - Total operating costs amounted to ¥79,398,196.77, up 25.5% from ¥63,275,046.96 in the prior period[24]. - Research and development expenses were ¥4,979,563.71, slightly up from ¥4,417,426.80 in the previous period[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,473[13]. - The company completed its initial public offering (IPO) of 24,174,035 shares, increasing total shares from 72,522,105 to 96,696,140 shares[18]. - The company has a total of 73,770,451 restricted shares, with no new restricted shares added during the reporting period[17].